Telitacicept for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–70 years old.
- You have IgA nephropathy confirmed by a kidney biopsy.
- You have at least 0.75 grams of protein in your urine per day (or a ratio of 0.6 g/g).
- Your kidney function (eGFR) is 25 or higher.
- You have been on a stable dose of blood pressure medicine (ACE inhibitor or ARB) for at least 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This study tests a medicine called telitacicept for children with IgA nephropathy or IgA vasculitis nephritis, two kidney diseases that cause protein in the urine. The goal is to see if the medicine can reduce protein loss and help protect the kidneys.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests two study medicines, zigakibart and atrasentan, together for adults with a kidney disease called IgA nephropathy. The goal is to see if this combination helps protect kidney function and reduces protein in the urine.
This trial tests a new medicine called telitacicept for children with a kidney condition called IgA vasculitis nephritis. The medicine aims to reduce kidney damage by calming the immune system. Participation may help your child's kidneys stay healthier.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.